|Articles|June 1, 2003
- BioPharm International-06-02-2003
- Volume 2003 Supplement
- Issue 1
Part 1: Skin, Bone, and Cells
Author(s)Gail Sofer
by Gail Sofer, BioReliance
Advertisement
Articles in this issue
over 22 years ago
BioPharm International's Virus Inactivation Series: A Prefaceover 22 years ago
Part 4: Culture Media, Biotechnology Products, and Vaccinesover 22 years ago
Inactivation of Viruses: An Introduction to the Seriesover 22 years ago
Part 6: Inactivation Methods Grouped by Virusover 22 years ago
Part 5: Disinfectionover 22 years ago
Part 2: Red Blood Cells and PlateletsNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
New Lymphoma Indication for CAR T-Cell Therapy Shapes Pipeline
2
Implementing Automation and Flexible Design for Allogeneic Manufacturing
3
Neurimmune and AstraZeneca Expand Efforts to Accelerate Fibril-Depleting Therapies
4
Emerging siRNA Platform Offers New Metabolic Disorder Therapies
5

